[EVENT] ISPOR Europe 2018
10-14 November 2018, Barcelona – Booth #501
ISPOR, the world’s leading organization for health economics & outcomes research, has invited Ipsos to present 18 posters at its forthcoming conference in Barcelona.
Our 18 posters – based on proprietary Real World Evidence and expertise in HEOR and Market Access – represent the combined strengths of Ipsos and our new colleagues, the former global healthcare team of GfK!
Please visit our newly extended team at Booth #501.
Below is a list of our poster sessions. We look forward to seeing you in Barcelona.
|
PRESENTATION TITLE |
SESSION |
DATE |
DISPLAY HOURS |
|
RELATIVE VALUE ASSESSMENT OF TREATMENTS FOR RARE DISEASES |
I |
Monday, Nov 12, 2018 |
08:45 – 13:45 |
|
CLINICAL CHARACTERISTICS OF BIOLOGIC ELIGIBLE HIDRADENITIS SUPPURATIVA PATIENTS IN EU5 |
I |
Monday, Nov 12, 2018 |
08:45 – 13:45 |
|
KILL/REPLACE/REGULATE: MOLECULAR-LEVEL VIEW OF TREATING DISEASE, EMERGING SOLUTIONS AND IMPLICATIONS FOR THE FUTURE OF HEALTHCARE |
I |
Monday, Nov 12, 2018 |
08:45 – 13:45 |
|
IS DIGITAL TECHNOLOGY BRINGING THE ADOPTERS CLOSER TO THE DECISION MAKERS? A COMPARATIVE ASSESSMENT ACROSS FIVE EUROPEAN MARKETS |
I |
Monday, Nov 12, 2018 |
08:45 – 13:45 |
|
GENE THERAPY CRISIS: HOW WILL THE CURRENT PIPELINE AFFECT THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE SYSTEMS? |
I |
Monday, Nov 12, 2018 |
08:45 – 13:45 |
|
HOSPITALIZATION RATES AMONG EMERGENCY ROOM-DIAGNOSED HIV+ PATIENTS IN THE US AND EU5 |
II |
Monday, Nov 12, 2018 |
15.45 – 19.15 |
|
DELAY BETWEEN HIV DIAGNOSIS AND TREATMENT INITIATION ACROSS THE EU5 |
II |
Monday, Nov 12, 2018 |
15.45 – 19.15 |
|
CLINICAL CHARACTERISTICS OF BIOLOGIC TREATED CROHN’S DISEASE PATIENTS WITH AND WITHOUT PRIOR SURGERY IN EUROPEAN UNION |
III |
Tuesday, Nov 13, 2018 |
08:45 – 13:30 |
|
IDENTIFYING THE CHANGES REQUIRED IN HEALTH TECHNOLOGY ASSESSMENT SYSTEMS IF OUTCOMES ARE TO BE OPTIMIZED IN A DIGITAL WORLD WHERE PERSONALIZED DATA AND PRECISION MEDICINE COLLIDE |
III |
Tuesday, Nov 13, 2018 |
08:45 – 13:30 |
|
THE EFFECT OF EUNETHTA ASSESSMENTS ON NATIONAL HTA DECISION MAKING |
III |
Tuesday, Nov 13, 2018 |
08:45 – 13:30 |
|
IS THE EUROPEAN BIOSIMILARS MEDICINES MARKET BECOMING UNSUSTAINABLE? AN EXPLORATION OF THE COMBINED IMPACT OF COMPETITION, INTERCHANGEABILITY, PROCUREMENT AND PRICING |
III |
Tuesday, Nov 13, 2018 |
08:45 – 13:30 |
|
DIRECTIVE 2004/18/EC: IMPLICATIONS FOR PUBLIC MEDICINE PROCUREMENT IN EUROPE |
III |
Tuesday, Nov 13, 2018 |
08:45 – 13:45 |
|
COMPARATIVE ANALYSIS OF BIOSIMILAR RITUXIMAB USAGE IN TREATING NON-HODGKIN LYMPHOMA AND RHEUMATOID ARTHRITIS: RESULTS FROM A MULTI-COUNTRY STUDY IN EUROPE |
III |
Tuesday, Nov 13, 2018 |
08:45 – 13:30 |
|
30-DAY MORTALITY RATES FOLLOWING HOSPITAL ADMISSION FOR ULCERATIVE COLITIS AND CLOSTRIDIUM DIFFICILE INFECTION |
III |
Tuesday, Nov 13, 2018 |
08:45 – 13:30 |
|
COMPARATIVE ANALYSIS OF ESMO MAGNITUDE OF CLINICAL BENEFIT SCALE VALUES ASSIGNED TO NSCLC CANCER DRUGS, VERSUS REAL WORLD DATA ON PRESCRIBING ACTIVITY AND LEVELS OF SATISFACTION IN THE EU5 |
III |
Tuesday, Nov 13 2018 |
08.45 – 13.15 |
|
DECREASED WORK PRODUCTIVITY AND INCREASED HEALTHCARE RESOURCE UTILISATION (HRU) AMONG PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) – RESULTS FROM A REAL WORLD EVIDENCE STUDY |
III |
Tuesday, Nov 13 2018 |
08.45 – 13.30 |
|
HUMANISTIC BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) – IN THE FIRST REAL-WORLD CROSS-SECTIONAL STUDY, SYMPTOMATIC NASH PATIENTS REPORT WORSE QUALITY OF LIFE |
III |
Tuesday, Nov 13 2018 |
08.45 – 13.30 |
|
UTILIZING ADVANCED DATA ANALYSIS AND VISUALIZATION, POWERED BY ARTIFICIAL INTELLIGENCE, TO ANALYZE PRICE MIGRATION DATA FOR ONCOLOGY PRODUCTS |
IV |
Tuesday, Nov 13 2018 |
15:30-19:00 |
|
COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN WESTERN EUROPE |
V |
Wednesday, Nov 14, 2018 |
08.45 – 13.15 |
|
COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN THE UNITED STATES |
V |
Wednesday, Nov 14, 2018 |
08.45 – 13.15 |
